Dysregulation of the Cannabinoid System in Childhood Epilepsy: From Mechanisms to Therapy
International Journal of Molecular Sciences · 27.06.2025 · 26 (13) · 6234
DOI: 10.3390/ijms26136234 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.06.2025. Verfasst von Gloria Montebello und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta, 2080 Msida, Malta. Hauptthemen laut MEDLINE: Epilepsy, Endocannabinoids, Cannabinoids, Drug Resistant Epilepsy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 238 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Epilepsy affects over 12 million children worldwide, with approximately 30% classified as having drug-resistant epilepsy (DRE), often accompanied by neuropsychiatric comorbidities that severely impact quality of life. The endocannabinoid system (ECS) functions as a multifaceted neuromodulatory network regulating neuronal excitability, synaptic plasticity, and immune homeostasis from early life through adolescence and into aging. In pediatric epilepsies, alterations in ECS components, particularly CB1 receptor expression and endocannabinoid levels, reveal disorder-specific vulnerabilities and therapeutic opportunities. Cannabidiol (CBD), a non-psychoactive compound from Cannabis sativa, has shown strong preclinical and clinical efficacy in treating DRE and is approved for Dravet syndrome, Lennox–Gastaut syndrome, and Tuberous Sclerosis Complex. Other ECS-based strategies, such as the use of CB1 receptor-positive allosteric modulators, can selectively enhance endogenous cannabinoid signaling where and when it is active, potentially reducing seizures in conditions like Dravet and absence epilepsy. Similarly, FAAH and MAGL inhibitors may help restore ECS tone without directly activating CB1 receptors. Precision targeting of ECS components based on regional expression and syndrome-specific pathophysiology may optimize seizure control and associated comorbidities. Nonetheless, long-term pediatric use must be approached with caution, given the critical role of the ECS in brain development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta, 2080 Msida, Malta.
- School of Biosciences, Cardiff University, Cardiff CF10 3AT, UK.
- College of Medicine, Korea University, Seoul 02841, Republic of Korea.
- Department of Medical and Surgical Sciences, University of Magna Graecia, 88100 Catanzaro, Italy.
ORCID-Profile: Giuseppe Di Giovanni
Zitieren
APA
Montebello, G., & Di Giovanni, G. (2025). Dysregulation of the Cannabinoid System in Childhood Epilepsy: From Mechanisms to Therapy. International Journal of Molecular Sciences, 26(13), 6234. https://doi.org/10.3390/ijms26136234
Vancouver
Montebello G, Di Giovanni G. Dysregulation of the Cannabinoid System in Childhood Epilepsy: From Mechanisms to Therapy. International Journal of Molecular Sciences. 2025;26(13):6234. doi:10.3390/ijms26136234
BibTeX
@article{Montebello2025,
author = {Montebello, Gloria and Di Giovanni, Giuseppe},
title = {Dysregulation of the Cannabinoid System in Childhood Epilepsy: From Mechanisms to Therapy},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {13},
pages = {6234},
doi = {10.3390/ijms26136234}
}
EUVIMED